WestHill Financial Advisors’s CytomX Therapeutics CTMX Stock Holding History

WestHill Financial Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$46.5K	Hold	17,082	–	–	0.01%	92
2026 Q2	$64.1K	Hold	17,082	–	–	0.01%	82
2026 Q1	$80.3K	Hold	17,082	–	–	0.02%	76
2025 Q4	$72.8K	Hold	17,082	–	–	0.01%	81
2025 Q3	$54.5K	Hold	17,082	–	–	0.01%	78
2025 Q2	$38.8K	Hold	17,082	–	–	0.01%	72
2025 Q1	$10.9K	Hold	17,082	–	–	﹤0.01%	73
2024 Q4	$17.6K	Hold	17,082	–	–	﹤0.01%	78
2024 Q3	$20.2K	Hold	17,082	–	–	﹤0.01%	75
2024 Q2	$20.8K	Hold	17,082	–	–	0.01%	70
2024 Q1	$37.2K	Hold	17,082	–	–	0.01%	76
2023 Q4	$26.5K	Hold	17,082	–	–	0.01%	75
2023 Q3	$22K	Hold	17,082	–	–	0.01%	95
2023 Q2	$29.4K	Hold	17,082	–	–	0.01%	89
2023 Q1	$25.8K	Hold	17,082	–	–	0.01%	89
2022 Q4	$27.3K	Hold	17,082	–	–	0.01%	91
2022 Q3	$25K	Hold	17,082	–	–	0.01%	84
2022 Q2	$31K	Hold	17,082	–	–	0.01%	85
2022 Q1	$46K	Hold	17,082	–	–	0.01%	90
2021 Q4	$74K	Hold	17,082	–	–	0.02%	89
2021 Q3	$87K	Buy	+17,082	New	+$91.4K	0.03%	71
2021 Q1	$132K	Hold	17,082	–	–	0.05%	58
2020 Q4	$112K	Buy	+17,082	New	+$122K	0.04%	59

Other funds holding CTMX

CPC

Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return

IRC

Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

WestHill Financial Advisors's CTMX Position: Q3 2026 in Review

WestHill Financial Advisors held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 17,082 shares worth $46.5K. The position accounts for 0.01% of the portfolio, ranked #92.

WestHill Financial Advisors first reported a position in CTMX in Q4 2020 and has held it in 23 quarters since. The position peaked at $132K in Q1 2021. 5 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

WestHill Financial Advisors held 17,082 shares of CytomX Therapeutics worth $46.5K as of Q3 2026.
WestHill Financial Advisors left its CytomX Therapeutics share count unchanged in Q3 2026.
CytomX Therapeutics made up 0.01% of WestHill Financial Advisors's portfolio in Q3 2026, its #92 holding.
WestHill Financial Advisors first reported a position in CytomX Therapeutics in Q4 2020 and has held it in 23 quarters since.
WestHill Financial Advisors's CytomX Therapeutics position peaked at $132K in Q1 2021.
5 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on WestHill Financial Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.